BTG plc, of London, said its licensed rights to two compounds to treat anxiety and depression to Abiogen Pharma SpA, a private Italian company, for an initial 2 million [pounds sterling] (US$3.2 million) and development milestones and royalties on sales. (Other News To Note).(Brief Article)

BTG plc, of London, said its licensed rights to two compounds to treat anxiety and depression to Abiogen Pharma SpA, a private Italian company, for an initial 2 million [pounds sterling] (US$3.2 million) and development milestones and royalties on sales. The compounds are the first in a new class of nonsedating, …